ProCE Banner Activity

Recent Advances in Oral Therapies for HR+/HER2- Breast Cancer: A Pharmacy Perspective

Clinical Thought
In this commentary, we discuss updates on the use of oral targeted therapies for the treatment of HR-positive/HER2-negative early and metastatic breast cancer, adverse event management, and tools for adherence.

Released: April 25, 2022

Expiration: April 24, 2023

No longer available for credit.

Share

Faculty

Allison Butts

Allison Butts, PharmD, BCOP

Pharmacist Manager, Oncology
Clinical Pharmacist, Breast Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
Assistant Adjunct Professor, UK College of Pharmacy
UK HealthCare
Lexington, Kentucky

Kristina F. Byers

Kristina F. Byers, PharmD, BCOP

Clinical Pharmacy Specialist
Breast Oncology
Emory Winship Cancer Institute
Atlanta, Georgia

Provided by

Provided by ProCE, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Allison Butts, PharmD, BCOP

Pharmacist Manager, Oncology
Clinical Pharmacist, Breast Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
Assistant Adjunct Professor, UK College of Pharmacy
UK HealthCare
Lexington, Kentucky

Allison Butts, PharmD, BCOP, has disclosed that she has received consultant/adviser/speaker fees from AstraZeneca and BeyondSpring.

Kristina F. Byers, PharmD, BCOP

Clinical Pharmacy Specialist
Breast Oncology
Emory Winship Cancer Institute
Atlanta, Georgia

Kristina F. Byers, PharmD, BCOP, has disclosed that she has received consulting fees from Seagen and has been a speaker for Wellstat Therapeutics.